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INTRODUCTION
Inherited factor VII (FVII) deficiency is one of the rare
inherited bleeding disorders, with an approximate
prevalence of about 1 in 500,000 in its severe form, to
one in 350 in the heterozygous state.1,2 In Pakistan,
inherited FVII deficiency is one of the commonest rare
bleeding disorders, in part, due to traditional consan-
guineous marriages.3
Factor VII deficiency presents with a wide clinical hetero-
geneity characterized by poor correlation of factor level
with bleeding.4 Clinical features are variable ranging
from mild or even asymptomatic forms to lethal cerebral
hemorrhages. Paradoxically, besides bleeding FVII
deficiency is also associated with thrombosis. Both
venous and arterial thrombosis has been reported in
approximately 3 to 4 percent of patients with FVII
deficiency.5 Most of these have been reported after the
use of factor replacement therapy or coexisting inherited
or other acquired thrombotic risk factors.6 In rare cases,
FVII-deficient patients present with spontaneous
thrombosis as well.
Here, we report a case of FVII deficiency and cerebral
venous sinus thrombosis (CVST) and a review of
management of such cases.
CASE REPORT
In September 2015, a 40-year female (gravidity 0, parity 0)
with no known comorbids, presented to emergency with
complaints of jerky movements in the left arm and
headache for three days. Her past history was
unremarkable apart from irregular menstrual cycles
without menorrhagia for which she was taking tablet
norethisterone, 5 mg, thrice daily for 21 days every
month for past three months. There was no family or
personal history of abnormal bleeding. Examination
revealed decreased power of left upper limb only.
Contrast enhanced computerized tomography (CT) scan
of brain, done as a part of initial workup of abnormal limb
movement and headache, showed deep CVST involving
all sinuses more marked on the right side extending into
the right internal jugular vein without intracranial
haemorrhage or infarct (Figure 1).
Other routine laboratory workup showed haemoglobin
13 g/dl (normal: 11.1 - 14.5 g/dl), white blood cell count
14 x 109/L (normal: 4 - 1 0 x 109/L), platelets 337 x 109/L
(normal: 150 - 400 x 109/L) and no abnormality detected
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ABSTRACT
Factor VII (FVII) deficiency is one of the rare inherited bleeding disorders. Thrombosis has been occasionally described
in inherited FVII deficiency. Here, we report a young female with undiagnosed FVII deficiency who presented with cerebral
venous sinus thrombosis (CVST). Oral contraceptive pill was found to be prothrombotic risk factor. The CVST occurred in
spite of the congenital FVII deficiency indicating that no definitive antithrombotic protection is assured by this defect. Low
molecular weight heparin and anti-Xa assay were found to be safe choice of anticoagulation and monitoring, respectively,
in this patient.
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Figure 1: Sagittal view of skull showing filling defect (thrombus) involving all
deep cerebral venous sinuses.
on peripheral smear. Coagulation studies revealed
prothrombin time (PT) 27 seconds (sec) (control
9-14 sec), INR 2.6 (control ratio ≤ 1) and activated partial
thromboplastin time (APTT) 25 sec (control 25-35 sec).
Liver function and renal profile was normal. ANA and
anti-DNA tests were negative. Anticardiolipin IgM was
2.26 MPL unit/ml (normal range ≤ 7 MPL unit /ml). In
view of incidental finding of prolonged PT in the absence
of bleeding symptoms, PT mixing study was ordered that
showed correction of PT with normal plasma (immediate
and after incubation at 37°C for 2 hours) and aged
serum. Subsequently, FVII level was checked and
found to be 14%. The findings were suggestive of FVII
deficiency.
Heritable thrombophilia workup was also performed and
showed normal protein S: 85% (60-110%), protein C:
89% (normal: 72-160%), antithrombin III: 92% (normal:
80-120%) and activated protein C resistance: 0.92
(normal: 0.86-1.1 ratio). Homocysteine levels were
found to be 12µmol/L (normal: 5 -12 µmol/L).
For CVST, the patient was started on subcutaneous
injections of low molecular weight heparin (LMWH)
Enoxaparin, 60mg, twice daily to which she responded
well with improvement of presenting symptoms.
Anticoagulation was monitored clinically and with anti-
Xa assay. No FVII levels were repeated during follow-
ups as there were no bleeding symptoms at all. During
hospital stay and subsequent follow-ups in anticoagulation
clinic, she remained well with normalization of left arm
movement. Until the follow-up in December 2015, no
bleeding was reported and anti-Xa remained in
therapeutic range. The patient gave her informed
consent prior to inclusion in the study.
DISCUSSION
A thrombotic manifestation in a patient congenitally pre-
disposed to bleeding always represents an exceptional
event. To date, occurrence of thromboembolic events in
FVII-deficient patients have been reported in several
individual cases and few case series; and in most of
these cases, thrombosis was related to replacement
therapies, surgical interventions, and delivery or
heritable thrombophilia factors.7,8 In this case, an oral
contraceptive pill was considered to be an associated
thrombotic risk factor. The workup for heritable,
thrombophilia was found to be normal. However,
prothrombin gene and factor V Leiden mutation could
not be performed because our facility lacks this capacity.
Therefore, the possibility of additional prothrombotic risk
factors cannot be entirely excluded.
The type of underlying mutation of FVII like Arg294Val
and Arg304Gln are also reported to be associated with
thrombotic event.9 In our case, amino acid sequencing
and nucleic acid sequencing could not be performed due
to non-availability of these tests at our setup.
In a study conducted by Mariani et al., thrombosis in FVII
deficient patient was not associated with any specific
phenotype, mutation zygosity or any specific factor level
cut-off.8 Hence, the exact cause of thrombosis in factor
VII deficient patients still remains unclear.
International consensus guidelines for treatment
modalities of the thromboembolic events in rare bleeding
disorders are lacking. In addition, sparse information is
found in literature related to the clinical management of
thrombosis in inherited FVII deficiency. Arellano-Rodrigo
et al. reported two cases highlighting the difficulty in
management, where one of the patients experienced
mucosal bleeding. Both the patients received warfarin as
initial anticoagulation therapy.10 Use of LMWH by
Klovaite et al. for a FVII deficient patient with vena porta
thrombosis was also associated with bleeding.7 On the
other hand, LMWH was found to be safe anticoagulation
alternative in our patient. However, optimal doses and
safety remain to be defined. In the same way, the safety
profile of new direct oral anticoagulants needs to be
investigated for treating thrombosis in rare bleeding
disorders.
To conclude, we have reported the concomitant
occurrence of CVST and a hemorrhagic disorder. This
case supports previous observations and demonstrates
that a risk of thrombosis should be considered in the
presence of inherited FVII deficiency. However, the
choice of anticoagulant treatment and prophylaxis needs
to be defined.
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